63,729 Shares in AngioDynamics, Inc. $ANGO Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the second quarter, HoldingsChannel reports. The firm acquired 63,729 shares of the medical instruments supplier’s stock, valued at approximately $829,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of AngioDynamics during the fourth quarter worth about $27,000. State of Wyoming acquired a new stake in AngioDynamics during the second quarter worth approximately $31,000. Russell Investments Group Ltd. boosted its position in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ANGO shares. Canaccord Genuity Group boosted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. HC Wainwright lifted their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and an average target price of $19.50.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $15.75 on Friday. AngioDynamics, Inc. has a one year low of $9.06 and a one year high of $16.29. The company has a 50 day moving average price of $13.96 and a 200 day moving average price of $12.05. The firm has a market capitalization of $650.95 million, a price-to-earnings ratio of -18.10 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The company had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities analysts forecast that AngioDynamics, Inc. will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.00% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.